Publication | Closed Access

Self-targeted polymersomal co-formulation of doxorubicin, camptothecin and FOXM1 aptamer for efficient treatment of non-small cell lung cancer

Drug TargetingOncologySelf-targeted Polymersomal Co-formulationEngineeringPolymer-drug ConjugateMedicineTumor TargetingFoxm1 AptamerAnti-cancer AgentTargeted TherapyLung CancerEfficient TreatmentPharmacologyCancer TreatmentChemotherapyBiomolecular Engineering